Two Sigma Investments LP Buys 67,403 Shares of Personalis, Inc. (NASDAQ:PSNL)

Two Sigma Investments LP raised its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 86.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 145,662 shares of the company's stock after purchasing an additional 67,403 shares during the quarter. Two Sigma Investments LP owned 0.21% of Personalis worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of PSNL. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Personalis during the 4th quarter valued at $28,000. OMERS ADMINISTRATION Corp bought a new position in Personalis in the fourth quarter valued at $470,000. Lightspeed Management Company L.L.C. purchased a new stake in Personalis during the fourth quarter valued at about $47,169,000. Jefferies Financial Group Inc. lifted its stake in Personalis by 104.1% during the fourth quarter. Jefferies Financial Group Inc. now owns 39,600 shares of the company's stock worth $229,000 after purchasing an additional 20,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Personalis during the fourth quarter worth about $348,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PSNL. Guggenheim initiated coverage on Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective on the stock. HC Wainwright increased their price target on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Craig Hallum initiated coverage on shares of Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $7.67.

Personalis Stock Performance

PSNL traded up $0.13 on Tuesday, hitting $5.53. 950,981 shares of the company were exchanged, compared to its average volume of 1,034,487. The stock has a market capitalization of $488.44 million, a PE ratio of -3.29 and a beta of 1.86. Personalis, Inc. has a 12 month low of $1.14 and a 12 month high of $7.20. The firm has a fifty day simple moving average of $4.21 and a two-hundred day simple moving average of $4.51.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The company had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. On average, equities analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.